Let's look closer

A portfolio of innovation
Exploring the new science of mental healthcare

ATAI Life Sciences is dedicated to bringing innovation to mental healthcare, a field that has seen little progress since the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the 1980s and 1990s, respectively. In particular, ATAI sees significant potential in 5HT2A agonists, atypical opioids, as well as drugs that act on the glutamatergic and GABAergic systems.

Want to learn more about our compounds? Take a deep dive below.

Psilocybin

Psilocybin

Explore the potential of psilocybin therapy for patients with treatment-resistant depression.
Learn more

Deuterated Etifoxine

Deuterated Etifoxine

Learn how GRX-917 (deuterated etifoxine) promises to transform the treatment landscape for those with anxiety disorders.
Learn more

Arketamine

Arketamine

Learn how arketamine may be more effective than esketamine for treatment-resistant depression.
Learn more

Ibogaine

Ibogaine

Recent studies have shown ibogaine to be exceptionally promising as treatment for opioid use disorder
Learn more